Ligand

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer

Retrieved on: 
Thursday, March 16, 2023
POC, Therapy, Immunoglobulin G, LILRB2, Pembrolizumab, Neoplasm, Platinum, Patient, PD-L1, RECIST, Ligand, PD-1, Ovarian cancer, Pharmaceutical industry

The INNATE trial evaluates JTX-8064 as a monotherapy and in combination with the PD-1 inhibitor pimivalimab in patients with advanced solid tumors.

Key Points: 
  • The INNATE trial evaluates JTX-8064 as a monotherapy and in combination with the PD-1 inhibitor pimivalimab in patients with advanced solid tumors.
  • A data review was conducted on March 15, 2023 to assess the potential to achieve proof-of-concept (POC) in the ovarian cancer combination cohort of the INNATE trial.
  • In this cohort, 35 patients with third- and fourth-line platinum resistant ovarian cancer were treated with JTX-8064 and Jounce’s PD-1 inhibitor, pimivalimab.
  • The combination was well tolerated with

AIM ImmunoTech Issues Letter to Stockholders

Retrieved on: 
Monday, March 6, 2023
Recurrence, Ligand, Patient, Cancer, Rintatolimod, Publication, DSM-IV codes, COVID-19, Arrow, Viral, Marker, Vaccine

OCALA, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today issued a letter to stockholders highlighting key accomplishments in 2022 and outlining corporate objectives for 2023.

Key Points: 
  • With 10 active clinical programs, 2023 is poised to be a busy and exciting year.
  • With this in mind, we plan to commence quarterly conference calls in the first quarter of 2023.
  • We had a truly transformative 2022, but believe 2023 holds significant potential as we advance toward a number of targeted milestones ahead.
  • On behalf of the entire Company, we are grateful for the continued support of our stockholders and remain committed to generating near- and long-term value for all stakeholders.

New platform set to accelerate early-stage targeted protein degradation programmes

Retrieved on: 
Thursday, March 9, 2023
Protein, DEL, DMPK, Chemistry, IND, ASMS, ChromeOS, Triage, Drug discovery, Ligase, TPD, Biology, Ligand, ADME, PROTAC, Pharmaceutical industry, Palladium, Fine chemical

Developed in-house at Sygnature Discovery, CHARMED is a technology platform designed to accelerate and support early-stage targeted protein degradation (TPD) programmes.

Key Points: 
  • Developed in-house at Sygnature Discovery, CHARMED is a technology platform designed to accelerate and support early-stage targeted protein degradation (TPD) programmes.
  • Dr Roland Hjerpe is Senior Principal Scientist, Bioscience at Sygnature Discovery and leads the targeted protein degradation work.
  • He says: "In most cases, targeted protein degradation relies on bringing a ubiquitin ligase into close proximity with a target protein.
  • The platform provides a quick way to collect data and triage a large number of molecules into a smaller set.

2023 SPE International Polyolefins Conference Announces Program and Plenary Speakers

Retrieved on: 
Tuesday, February 28, 2023
Carbon, Outlook, Dow Jones, Value, Policy, Integration, Conference, Carbon footprint, Borealis, Business development, Heartland Petrochemical Complex, Video game, Ligand, Northwestern University

HOUSTON, Feb. 28, 2023 /PRNewswire-PRWeb/ -- The 2023 SPE International Polyolefins Conference, the largest polymer conference in the world dedicated to Polyolefins, will be a Hybrid Conference (both in-person and virtual) on March 5-8, 2023. The in-person Conference will be held in the picturesque Galveston Convention Center in Galveston, TX over looking the beach. There will be over 100 presentations, a Sunday afternoon tutorial, 56 Exhibitor booths, 14 Sponsors, over 1,000 people expected to attend, two Networking Socials, and a Student Poster Competition.

Key Points: 
  • The 2023 SPE International Conference (March 5-8), the largest polymer conference in the world dedicated to Polyolefins, announces their program with over 100 speakers.
  • HOUSTON, Feb. 28, 2023 /PRNewswire-PRWeb/ -- The 2023 SPE International Polyolefins Conference, the largest polymer conference in the world dedicated to Polyolefins, will be a Hybrid Conference (both in-person and virtual) on March 5-8, 2023.
  • The in-person Conference will be held in the picturesque Galveston Convention Center in Galveston, TX over looking the beach.
  • The purpose of the conference is for companies to meet with their customers and suppliers, to learn about new technology/market trends, and to network.

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Retrieved on: 
Monday, February 27, 2023
Clinical trial, RAGE (receptor), Safety, Ligand, Breast cancer, News, Cancer, Survival, Brain, Pancreatic cancer, Investigational New Drug, HMGB1, Receptor (biochemistry), FDA, Prognosis, Patient, S100 protein, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Letter, HIV disease progression rates, S100, RAGE, Food, Lung cancer, Pharmaceutical industry, Medical imaging, Glioblastoma

WESTON, Fla., Feb. 27, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) reviewed Cantex's Investigational New Drug application and issued a "Study May Proceed" letter for Cantex's Phase 2 clinical trial to assess the safety and therapeutic effect of azeliragon in patients with newly diagnosed unmethylated glioblastoma treated with standard of care radiation therapy. Azeliragon was recently granted FDA Orphan Drug Designation for the treatment of glioblastoma.

Key Points: 
  • Azeliragon was recently granted FDA Orphan Drug Designation for the treatment of glioblastoma.
  • "We are very pleased to have received this favorable response from the FDA enabling Cantex to initiate a Phase 2 clinical trial of azeliragon for the treatment of glioblastoma," commented Stephen G. Marcus, M.D., Chief Executive Officer of Cantex.
  • By preventing interaction of RAGE with these ligands, azeliragon may inhibit glioblastoma and overcome its resistance to effective treatment.
  • Dr. Marcus continued: "The Phase 2 trial of azeliragon in glioblastoma is one of several promising clinical programs we continue to advance with azeliragon to treat cancer and other diseases where RAGE is implicated.

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, February 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, Pachyonychia congenita, Coronavirus, Nevoid basal-cell carcinoma syndrome, RNA-dependent RNA polymerase, Maintenance, IND, Immunoglobulin A, MC, Focal segmental glomerulosclerosis, NDA, COPD, Jazz Pharmaceuticals, Basal-cell carcinoma, COVID-19, NMPA, SB206, Infection, Therapy, Pelican, Retirement, Syndrome, Marketing, Patient, Pneumonia, File, SARS-CoV-2, Telecanthus, Travers Smith, Kidney, Research, GAAP, Investment, RASP, Growth, Income tax, MLM, Total, NASH, FSGS, RNA, Acute myeloid leukemia, Telephone, IM, Depreciation, Forecasting, Quality of life, Microcystic lymphatic malformation, Verona, Molluscum contagiosum, BLA, Risk, FDA, EPS, Element, EMA, Communication, IV, Cryptocurrency, Pharmaceutical industry, Video game, Ligand, IgA nephropathy

Total revenues for the fourth quarter of 2022 were $50.4 million, compared with $56.4 million for the same period in 2021.

Key Points: 
  • Total revenues for the fourth quarter of 2022 were $50.4 million, compared with $56.4 million for the same period in 2021.
  • Core Captisol sales were $3.3 million for the fourth quarter of 2022, compared with $7.1 million for the same period in 2021.
  • Captisol sales related to COVID-19 were $23.5 million for the fourth quarter of 2022, compared with $28.3 million for the same period in 2021.
  • Contract revenue was $1.5 million for the fourth quarter of 2022, compared with $3.5 million for the same period in 2021.

KEYTRUDA Market Drug Insight and Market Forecast 2023-2032: Competition with other Emerging Therapies Heats Up - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 21, 2023
Health, Pharmaceutical, Clinical trial, MSI-H, Ligand, Pembrolizumab, Pancreatic cancer, Immune system, PD-1, Research, United Kingdom, FDA, PD-L1, PD-L2, Patient, EU4, SWOT, Neoplasm, Pharmaceutical industry, Palladium

The "KEYTRUDA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "KEYTRUDA Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Further, it also consists of future market assessments inclusive of the KEYTRUDA market forecast analysis for pancreatic cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in pancreatic cancer.
  • Other emerging products for pancreatic cancer are expected to give tough market competition to KEYTRUDA and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to KEYTRUDA for pancreatic cancer?

Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer

Retrieved on: 
Tuesday, January 17, 2023
Dark, University, Pan-Cancer Analysis, Erasmus, Immunotherapy, Aeris Naviter AN-2 Enara, Erasmus MC, CD55, Head, Ligand, Therapy, Patient, Laboratory, TCR, European, Doctor of Philosophy, Vaccine

ROTTERDAM, January 17, 2023 - Pan Cancer T B.V. , a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Dr. Rachel Abbott as Chief Scientific Officer.

Key Points: 
  • ROTTERDAM, January 17, 2023 - Pan Cancer T B.V. , a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Dr. Rachel Abbott as Chief Scientific Officer.
  • Prior to joining Pan Cancer T, Rachel Abbott had been Senior Director, Head of TCR Pipeline and Dark Antigen Research at Enara Bio from March 2021 to January 2023.
  • "We warmly welcome Rachel Abbott to our management team,” said Katrien Reynders-Frederix, CEO of Pan Cancer T. "Rachel has tremendous industry experience, including developing T cell therapies, leading scientific research teams and managing collaborations with big pharma and academic institutions.
  • "I am honored to take over the position as Pan Cancer T´s Chief Scientific Officer,” said Dr. Rachel Abbott.

Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics

Retrieved on: 
Tuesday, January 10, 2023
Disease, AMPS, Doctor of Philosophy, Biomarker, Informatics, Artificial intelligence, Ligand, Therapy, Drug discovery, Metabolism, Cancer, Chemistry, Pharmaceutical industry, PLEX

Atavistik Bio’s incorporation of Plex Research’s technology will enrich the informatics capabilities of its Atavistik Metabolite Protein Screening (AMPS) platform and accelerate its drug discovery pipeline.

Key Points: 
  • Atavistik Bio’s incorporation of Plex Research’s technology will enrich the informatics capabilities of its Atavistik Metabolite Protein Screening (AMPS) platform and accelerate its drug discovery pipeline.
  • The integration of Atavistik Bio’s AMPS data with Plex Research’s platform will create a unique and customizable data analysis engine to rapidly enable novel insights for drug discovery.
  • "Allosteric interactions, which we know can present novel druggable nodes for intractable targets, historically have been difficult to discover.
  • The synergies between our technology platforms are compelling, and we’re excited to see where it will take us.”

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IND, Degenerative disease, Autoimmune disease, Janssen, Hoffmann-La Roche, Ipilimumab, Lymphoma, Ovarian cancer, Monoclonal antibody, Janssen Biotech, Bispecific monoclonal antibody, CD28, Cytokine, ICOS, Tumor microenvironment, Psoriasis, ENPP3, RCC, Biology, CLDN6, NK, Immune system, Protein engineering, Ligand, Patient, Genentech, CD3, Atopic dermatitis, Research, Cancer, Claudin, CLDN9, Antibody, Lenalidomide, MCRPC, Vaccine, Pharmaceutical industry, Medicine, Medical imaging, Regulatory T cell

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.
  • “We are building on this momentum in 2023, progressing our clinical portfolio internally and with our co-development partners, including four bispecific antibody programs targeting solid tumors.
  • Xencor plans to:
    Continue enrolling patients into the Phase 1b, multiple-ascending dose study in patients with atopic dermatitis and psoriasis.
  • Xencor ended the fourth quarter of 2022 with unaudited cash, cash equivalents, receivables and marketable debt securities totaling approximately $610 million.